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Cibenzoline, 4,5-dihydro-Z- (2,2-diphenylcyclopropyl) -lH-imidazole, is a new 
class 1 antiarrhythmic drug chemically not related to any other class 1 anti- 
arrhythmic agent. The imidazole metabolite of cibenzoline, 2- (2,2-diphenyl- 
cyclopropyl) -lH-imidazole (I), is almost devoid of antiarrhythmic action [ 11. 
The efficacy of cibenzoline has been shown by several investigators in the 
treatment of supraventricular and ventricular arrhythmias [ 2-7 1. 
Although it is generally unnecessary to determine serum levels of anti- 
arrhythmic drugs, the determination of plasma levels is recommended in cases 
of side-effects, unexplained failure of drug therapy and possible drug interac- 
tions [8]. 
The aim of the present study was to develop a simple but accurate high- 
performance liquid chromatographic (HPLC) method to determine cibenzo- 
line and its metabolite (I) in human serum. 
EXPERIMENTAL 
Cibenzoline and its imidazole metabolite (I) were provided by Beiersdorf 
(Hamburg, F.R.G.). Acetonitrile, hydrochloric acid, triethylamine, dichloro- 
methane and sodium hydroxide were obtained from Merck (Darmstadt, 
F.R.G.). l-Octanesulphonic acid (PIC B-8 low-UV reagent) and dibutylamine 
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phosphate (PIC D-4 reagent) were from Waters Assoc. (Eschborn, F.R.G.) 
and butylamine was from Fluka (Buchs, Switzerland). The internal standard, 
p-chlorodisopyramide, was obtained from Albert-Russell ( Wiesbaden, F.R.G. ). 
Instrumentation 
The HPLC system consisted of a Model 721 system controller, a 510 HPLC 
pump, a Wisp 710B injector block, a Lambda-Max Model 481 variable-wave- 
length detector and a Model 730 data module (Waters Assoc. ). 
Chromatographic conditions 
The analysis was performed using a Nucleosil CN reversed-phase column 
(125 mm x 4.6 mm I.D., particle size 5 pm; Grom, Herrenberg, F.R.G.) at room 
temperature (20-24°C). The mobile phase consisted of 65% (v/v) A (971.5 
ml of water, 25 ml of PIC B-8 low-UV reagent, 1 ml of butylamine and 2.5 ml 
of PIC D-4 reagent) and 35% (v/v) B (acetonitrile). The flow-rate was 1.1 
ml/min. The column effluent was monitored at 214 nm, using a detector range 
of 0.05 a.u.f.s. and a chart speed of 0.4 cm/min. The injected volume was 200 
lul. 
Standards 
Three stock standard solutions were prepared, containing 10 mg/l cibenzo- 
line and I and 15 mg/l internal standard in 0.01 A4 hydrochloric acid, respec- 
tively. The solutions were stable for at least two months if stored at 4°C. A 
standard working solution was obtained by combining aliquots of the stock 
solutions and diluting them with 0.01 A4 hydrochloric acid to concentrations 
of either 1.0 mg/l cibenzoline and I or 1.5 mg/l for the internal standard. 
Sample collection 
Serum was obtained by centrifugation at 900 g for 10 min. Twenty-two drug- 
free serum samples from normal healthy volunteers (twelve male, ten female ) 
were pooled (normal pool). Through serum levels of cibenzoline from eighteen 
patients treated with cibenzoline for chemical conversion of atria1 fibrillation 
were obtained at the fifth day of oral treatment. Prior to the therapy with 
cibenzoline a serum sample was obtained and analysed from these patients to 
exclude interference with cibenzoline, I or the internal standard from co-med- 
ication in these patients. Co-medication was not changed during the treatment 
with cibenzoline and consisted of phenprocoumone (n= 18), furosemide 
(n=5), hydrochlorthiazide (n=6), triamterene (n= 6), metildigoxin (n= 12), 
digitoxin ( n = 6)) verapamil (n = 9) and ranitidine (n = 3 ) . Serum samples of 
patients treated with therapeutic doses of digitoxin, metildigoxin, verapamil, 
nifedipine, nitrendipine, dihydralazine, metoprolol, betaxolol, furosemide, 
xipamide, hydrochlorothiazide, triamterene, spironolactone, enalapril, isosor- 
bide-5-mononitrate, heparin, phenprocoumon, acetylsalicylic acid, diazepam 
and glibenclamide were analysed individually. None of these drugs was noted 
as an interfering spike in the determination of cibenzoline, I or the internal 
standard. 
Extraction procedure 
Dichloromethane (1.75 ml), 0.25 ml of triethylamine, 1.0 ml of serum, 100 
~1 of 1 M sodium hydroxide and 100 ~1 of the stock solution of the internal 
standard were introduced into a glass centrifuge tube (KZstner, Tiibingen, 
F.R.G.). The tube was closed with a stopper (Sarstedt, Niirmbrecht, F.R.G.), 
shaken (by slow rotation movement) for 20 min and centrifuged at 3600 g for 
20 min. Subsequently the serum phase was discarded, and 1.0 ml of the di- 
chloromethane-triethylamine phase was transferred to a clean glass tube and 
evaporated to dryness at room temperature (20-24 o C ) under a stream of ni- 
trogen. The residue was redissolved in 500 ,~l of 0.01 M hydrochloric acid. 
Linearity test 
The linearity of the chromatographic procedure was tested for cibenzoline, 
I and the internal standard by analysing nine standard solutions with concen- 
trations of 4.0, 3.0, 2.0, 1.5, 1.0, 0.5, 0.25, 0.1 and 0.05 mg/l for each of the 
components (Fig. 1) . At each concentration level three determinations were 
performed. 
The amount of each standard required to reach concentrations in the range 
0.05-4.0 mg/l was introduced into a glass centrifuge tube, and 1.0 ml of the 
normal pool serum was added. Subsequently the spiked serum samples were 
extracted and subjected to the chromatographic analysis. The linearity test of 
the entire procedure in serum was done over the same concentration range 
(Fig. 2). 
Fig. 1. Linearity test for ( 0 ) cibenzoline, (0 ) the imidazole metabolite and (A ) the internal 
standard in the standard solution. c (cib ) = concentration of cibenzohne; c (I) = concentration of 
the imidazole metabolite; c (is) = concentration of internal standard. 
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Fig. 2. Linear@ test for (0 ) cibenzoline, (0 ) the imidazole metabolite and (A ) the internal 
standard in a spiked serum sample. c (cib) =concentration of cibenzoline; c(I) ~concentratlon of 
the imidazole metabolite; c (is) =concentration of internal standard. 
Recoveries 
The recoveries were determined by comparing the peak areas of cibenzoline, 
I and the internal standard obtained by analysing a spiked serum sample (100 
~1 of each stock solution standard plus 1.0 ml of the normal pool) with the peak 
areas obtained by direct injection of the standard working solution (1.0 mg/l 
cibenzoline, 1.0 mg/l I and 1.5 mg/l internal standard). 
Quantification 
Prior to injection of a sample from a patient, a sample of the working stan- 
dard solution of cibenzoline, I and the internal standard containing 1 mg/l of 
each substance was injected. Since the linearity test showed a linear relation- 
ship between the peak area and the concentration of cibenzoline and I (Figs. 
1 and 2), the concentrations of cibenzoline and I in the patient’s sample were 
calculated as follows: 
APS* 1 mg/l 
ASW 
= concentration (mg/l) of cibenzoline or I in the patient’s sample (CPS) 
where APS is the peak area of cibenzoline or I in the patient’s sample and ASW 
is the peak area of cibenzoline or I in the standard working solution. 
Since the recovery of cibenzoline and I in the patient’s sample might change 
in various extractions we calculated the recovery rate by dividing the peak area 
of the internal standard in the patient’s sample by the peak area of the internal 
standard in the standard working solution. Then 
AISPS. 100 
AISSW 
= recovery ( % ) 
where AISPS is the peak area of the internal standard in the patient’s sample 
and AISSW is the peak area of the internal standard in the standard working 
solution. 
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The calculated concentrations of cibenzoline and I were finally corrected for 
the recovery rate as follows: 
CPS (mg/l)-100 
recovery (% ) 
= final concentration of cibenzoline or I (mg/l) 
The recovery rates of cibenzoline, I and the external standard were the same 
within ca. 5%. 
RESULTS 
For the standards and serum samples taken through the entire procedure 
there was a linear relationship between concentration and peak area over the 
total range tested. The recoveries (mean 2 S.D. ) were 96.3 + 4% for cibenzo- 
line (n = lo), 95.7 ‘_’ 6.3% for I (n= 10) and 95.4 +- 3.8% for the internal stan- 
dard (n = 10). The technical error of the apparatus was determined for ciben- 
zoline, I and the internal standard by injecting ten samples of the same standard 
working solution containing 1 mg/l cibenzoline, 1 mg/l I and 1.5 mg/l internal 
standard. The peak area of cibenzoline was 3.9589+_0.0187, that of I was 
3.9589 + 0.0151, and that of the internal standard was 4.3247 + 0.0394. 
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Fig. 3. Chromatograms of (A) a blank from the patient’s pool, (B) a standard working solution 
and (C ) the serum of a patient receiving oral cibenzolme (320 mg ) . 
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Fig. 4. Plasma levels (&I) inpatients successfully converted to sinus rhythm (n =6 ) and patients 
with persisting atria1 fibrillation (n = 12 ). 
A typical chromatogram obtained from the analysis of a serum sample of a 
patient receiving oral cibenzoline (320 mg per day) is shown in Fig. 3. 
Trough serum levels obtained with 260 mg of cibenzoline (0.156 + 0.067 mg/ 
1, n=8) daily were not significantly different from serum levels obtained in 
patients treated with 320 mg of cibenzoline (0.205 ? 0.113 mg/l, n= 10) daily. 
In the patient group receiving 260 mg as well as in the patient group treated 
with 320 mg of cibenzoline per day, three patients converted to sinus rhythm. 
Trough serum levels of cibenzoline were not significantly different between 
patients treated successfully with cibenzoline and patients with persisting atria1 
fibrillation (Fig. 4). 
DISCUSSION 
Four different methods for the determination of cibenzoline and its imida- 
zole metabolite have been published. Canal et al. [9] used a gas chromato- 
graphic (GC ) method, but the limit of detection was 30 ng/ml and the imida- 
zole metabolite could not be determined. A gas chromatographic-mass 
spectrometric assay has been reported by Min and Garland [lo], with a very 
good sensitivity of 1 ng/ml. Although GC procedures are specific and sensitive 
they are not always available in clinical laboratories. A radioimmunoassay de- 
veloped by Dixon et al. [ 111 showed good sensitivity, but the antiserum cross- 
reacted almost 100% with the imidazole metabolite. 
The only HPLC procedure reported [ 121 has a limit of quantitation of 10 
ng/ml and a moderate recovery rate of 60-70%: cibenzoline and the imidazole 
metabolite could not be determined simultaneously by this procedure, the re- 
covery of the imidazole metabolite was 88.5 + 8.7% in plasma, and the limit of 
quantitation was 10 ng/ml. 
The limit of quantitation in the assay reported here is 10 ng/ml, but the 
recovery is ca. 95% for cibenzoline. An advantage of our assay is the simulta- 
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neous determination of cibenzoline and the imidazole metabolite. The recov- 
ery and the limit of detection for the imidazole metabolite are comparable with 
those of cibenzoline. 
We determined cibenzoline serum levels in patients treated with cibenzoline 
for chemical conversion of newly developed atria1 fibrillation or flutter. Suc- 
cessful conversion to sinus rhythm was achieved in six of eighteen patients; 
however, serum levels were not significantly different between responders to 
cibenzoline and non-responders (Fig. 4). 
CONCLUSION 
A sensitive, selective and easy-to-perform HPLC assay with a high recovery 
for simultaneous determination of cibenzoline and its imidazole metabolite has 
been developed. Serum levels of cibenzoline and its imidazole metabolite were 
determined in patients after oral treatment with cibenzoline for chemical con- 
version of atria1 fibrillation. 
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